The United States Atomic Energy Commission first released radioiodine (I131) for general use in July, 1946. This material was made in the atomic pile at Oak Ridge. Investigations with the isotope were then initiated to determine the clinical value of the isotope in the diagnosis and treatment of hyperthyroidism, in addition to the studies in many other fields. Prior to this, radioiodine had been tried in the treatment of hyperthyroidism. Hertz and Roberts1 and later Chapman and Maloof2 had available to them I130, the 12-hour half-life isotope of stable iodine, made in the cyclotron. Hamilton and Lawrence3 employed I131, the 8-day half-life isotope. Except for the few patients treated by Soley with these latter investigators, I131 was not used further until the action of the Atomic Energy Commission; and at that time therapeutic interest in I130 virtually ceased.
The highly successful initial
Werner SC. OAK RIDGE RADIOIODINE (I131) FOR HYPERTHYROIDISM—TENTH ANNIVERSARYGUEST EDITORIAL. JAMA. 1956;161(7):628–629. doi:10.1001/jama.1956.02970070060016
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: